FDA Approves Afrezza Inhaled Insulin for Children Ages 6+: What Parents Need to Know

By Dr. Toni Kim, MD and Dr. Kelli Davis, DO | Life Pediatric Endocrinology

A Major Milestone in Pediatric Diabetes Care

For families living with Type 1 Diabetes (T1D), insulin injections have long been an unavoidable part of daily life. Now, for the first time, the U.S. Food and Drug Administration (FDA) has approved Afrezza® inhaled insulin for children and adolescents ages 6 and older, creating a new option for mealtime insulin management.

This FDA approval marks a major advancement in pediatric diabetes care and offers a needle-free alternative for mealtime insulin dosing.

For children who struggle with insulin injections, needle anxiety, or missed mealtime doses, Afrezza may provide a more convenient and acceptable treatment option.

At Life Pediatric Endocrinology, we continuously evaluate emerging therapies that may improve quality of life and diabetes outcomes for children and adolescents. Here is what families should know about this newly approved treatment.

What Is Afrezza?

Afrezza® is a rapid-acting inhaled insulin manufactured by MannKind Corporation. Unlike traditional rapid-acting insulins that are injected under the skin, Afrezza is delivered through a small handheld inhaler and absorbed through the lungs.

The medication begins working quickly after inhalation and is designed to help control blood sugar levels after meals.

Key takeaway: Afrezza provides mealtime insulin without an injection, making it the first FDA-approved inhaled insulin option available for children ages 6 and older.

Prior to this approval, Afrezza was available only for adults with diabetes. Children and adolescents can now access this therapy beginning at age six.

Which Children May Be Eligible?

Afrezza is approved for:

• Children and adolescents ages 6 years and older
• Patients with Type 1 Diabetes
• Patients with Type 2 Diabetes requiring mealtime insulin

For children with Type 1 Diabetes, Afrezza must still be used alongside a long-acting basal insulin.

Important: Afrezza is not a replacement for basal insulin and is used specifically for meal-related glucose control.

Families should think of Afrezza as a replacement for mealtime insulin injections—not for long-acting insulin therapy.

Why Is This Approval Important?

Many children experience significant stress related to insulin injections.

Common challenges include:

• Fear of needles
• Missed mealtime insulin doses
• Injection fatigue
• Social concerns at school or sports activities
• Reduced treatment satisfaction

A needle-free insulin option may improve treatment adherence, reduce anxiety, and enhance quality of life for many children and families.

For some children, simply reducing the number of injections each day can significantly improve confidence and consistency with diabetes management.

Better adherence often leads to better long-term diabetes outcomes.

What Did the Pediatric Clinical Trials Show?

The FDA approval was supported by the landmark INHALE-1 Trial, which evaluated inhaled Technosphere insulin (Afrezza) in children and adolescents with diabetes.

Study Design

The study included:

• 230 children and adolescents
• Ages 4–17 years
• Approximately 98% with Type 1 Diabetes
• Comparison of Afrezza versus traditional rapid-acting insulin analogs
• Follow-up duration of 26 weeks

Blood Sugar Control

Researchers found that:

• Average HbA1c outcomes were similar between treatment groups
• Continuous glucose monitoring (CGM) time-in-range was comparable
• Overall glycemic control was similar to traditional mealtime insulin therapy

Bottom line: Children using Afrezza achieved blood sugar control comparable to children using injected rapid-acting insulin.

Although the trial narrowly missed its formal statistical noninferiority endpoint, real-world glucose outcomes remained similar between groups.

Improved Treatment Satisfaction

One of the most encouraging findings was patient satisfaction.

Children using Afrezza reported:

• Greater treatment satisfaction
• Improved convenience
• Reduced burden associated with mealtime insulin administration

For many families, quality of life is just as important as laboratory values.

Managing diabetes successfully requires treatments that children can realistically maintain over many years.

Children are more likely to follow treatment plans when those treatments fit comfortably into daily life.

Less Weight Gain

Researchers also observed:

• Less weight gain
• Lower BMI increases

compared with children using traditional injected rapid-acting insulin.

This finding may be especially meaningful for adolescents concerned about weight changes associated with insulin therapy.

While additional long-term studies are needed, these early findings are encouraging.

What About Safety?

Safety was a major focus of the pediatric studies.

Lung Function

Investigators carefully monitored pulmonary function using spirometry.

Results showed:

• No significant difference in lung function between groups
• No meaningful decline in FEV₁ measurements
• No serious pulmonary safety concerns during the study

The available data showed reassuring lung safety outcomes in appropriately selected children.

An additional 52-week extension study continued to support the safety profile.

Researchers reported:

• No unexpected lung-related complications
• No clinically meaningful decline in pulmonary function
• Stable respiratory outcomes over time

Longer-term monitoring will continue, but current evidence supports a favorable safety profile.

Important Limitations and Precautions

While the approval is exciting, Afrezza is not appropriate for every child.

Baseline Lung Testing Is Required

Before starting treatment, children must undergo:

• Spirometry testing
• Measurement of FEV₁ (forced expiratory volume)

Lung function testing is required before beginning Afrezza therapy.

This helps ensure healthy lung function before treatment begins.

Not Recommended for Asthma or Chronic Lung Disease

Afrezza remains contraindicated in patients with:

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Certain chronic respiratory conditions

Children with asthma generally should not use Afrezza.

Because asthma is relatively common in children, careful screening is essential before prescribing this medication.

Dose Flexibility Can Be Challenging

The smallest available Afrezza cartridge contains 4 units of insulin.

For very young children or those requiring extremely small insulin doses, this may make fine dose adjustments more difficult compared with insulin pumps or traditional injections.

Children who need highly precise insulin dosing may still benefit more from insulin pumps or injectable insulin therapy.

How Does Afrezza Compare With Insulin Pumps?

Many children today use advanced diabetes technology, including:

• Hybrid closed-loop insulin pumps
• Automated insulin delivery systems
• Continuous glucose monitors

Afrezza is unlikely to replace insulin pumps for every child.

However, it may serve as an excellent option for:

• Children who dislike injections
• Families seeking a simpler mealtime solution
• Adolescents struggling with treatment adherence
• Patients not interested in pump therapy
• Patients needing occasional rapid correction doses

Afrezza is another tool in the diabetes toolbox—not necessarily a replacement for insulin pumps or advanced diabetes technology.

The best diabetes treatment remains the one that safely fits a child's lifestyle and can be used consistently.

Expert Perspective From Life Pediatric Endocrinology

The approval of Afrezza for pediatric use represents an important expansion of treatment options for children with diabetes.

At Life Pediatric Endocrinology, we are particularly encouraged by several findings:

• Comparable glucose control
• High patient satisfaction
• Minimal hypoglycemia
• Less weight gain
• Reassuring pulmonary safety data

The combination of effective glucose control and improved treatment satisfaction makes this approval especially noteworthy.

That said, Afrezza is not a universal solution.

Careful patient selection remains critical, especially in children with asthma, respiratory conditions, or those requiring highly precise insulin dosing.

The right diabetes treatment is highly individualized and should be determined in partnership with a pediatric endocrinologist.

As pediatric endocrinologists, our goal is always to match the right therapy to the right patient while balancing safety, effectiveness, convenience, and quality of life.

Frequently Asked Questions (FAQ)

Is Afrezza approved for children?

Yes. The FDA has approved Afrezza for children and adolescents ages 6 years and older with diabetes requiring mealtime insulin.

Does Afrezza replace long-acting insulin?

No. Children with Type 1 Diabetes must continue taking basal insulin.

Does Afrezza require lung testing?

Yes. Spirometry testing is required before starting treatment.

Can children with asthma use Afrezza?

Generally no. Afrezza is contraindicated in patients with asthma and certain chronic lung diseases.

Is Afrezza safer than insulin injections?

Current studies suggest a favorable safety profile, but each child should be individually evaluated by a pediatric endocrinologist.

Learn More About Pediatric Diabetes Care

At Life Pediatric Endocrinology, we provide concierge pediatric endocrinology services for children and adolescents with:

• Type 1 Diabetes
• Type 2 Diabetes
• Insulin pump management
• Continuous glucose monitoring
• Growth disorders
• Puberty concerns
• Thyroid disease
• Weight management

Our team helps families navigate both traditional and emerging therapies to create personalized treatment plans that fit each child's needs.

Wondering whether Afrezza may be right for your child? A consultation with a pediatric endocrinologist can help determine whether this new treatment option fits your child's diabetes management plan.

If you would like to learn whether Afrezza may be appropriate for your child, schedule a consultation with our pediatric endocrinology team.

About the Authors

Dr. Toni Kim

Dr. Toni Kim is a board-certified pediatric endocrinologist and founder of Life Pediatric Endocrinology. She specializes in the diagnosis and treatment of childhood endocrine disorders, with particular expertise in growth disorders, puberty concerns, and Type 1 Diabetes. Dr. Kim works closely with children and families to develop individualized treatment plans that support healthy growth, development, and long-term metabolic health.

Dr. Kelli Davis

Dr. Kelli Davis is a board-certified pediatric endocrinologist at Life Pediatric Endocrinology with specialized expertise in growth disorders, puberty disorders, metabolic bone health, and Type 1 Diabetes. She has advanced training in the evaluation and management of pediatric bone and mineral disorders and cares for children with a wide range of endocrine conditions, including diabetes, growth concerns, and pubertal development issues.

Together, Dr. Kim and Dr. Davis provide comprehensive pediatric endocrine care and have extensive training and experience caring for children and adolescents living with Type 1 Diabetes.

References

1. FDA Approval Announcement – MannKind Corporation, 2026.
2. Haller MJ, Kanapka L, Monzavi R, et al. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes. Diabetes Care. 2025.
3. Beck RW, Kanapka L, Monzavi R, et al. Inhaled Technosphere Insulin in Children With Diabetes: The INHALE-1 Extension Study. Diabetes Technology & Therapeutics. 2026.
4. Ekhlaspour L, Kanapka L, Dewan A, et al. Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living With Type 1 Diabetes. Diabetes Technology & Therapeutics. 2026.